This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2018 Jun 12;137(24):2551-2553.

doi: 10.1161/CIRCULATIONAHA.118.035289. Epub 2018 Apr 11.

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine

Kershaw V Patel¹, Ambarish Pandey¹, James A de Lemos²

Affiliations

Affiliations

¹ Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
² Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas. james.delemos@utsouthwestern.edu.

PMID: 29643058
DOI: 10.1161/CIRCULATIONAHA.118.035289

Review

Conceptual Framework for Addressing Residual Atherosclerotic Cardiovascular Disease Risk in the Era of Precision Medicine

Kershaw V Patel et al. Circulation. 2018.

. 2018 Jun 12;137(24):2551-2553.

doi: 10.1161/CIRCULATIONAHA.118.035289. Epub 2018 Apr 11.

Authors

Kershaw V Patel¹, Ambarish Pandey¹, James A de Lemos²

Affiliations

¹ Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas.
² Department of Internal Medicine, Division of Cardiology, University of Texas Southwestern Medical Center, Dallas. james.delemos@utsouthwestern.edu.

PMID: 29643058
DOI: 10.1161/CIRCULATIONAHA.118.035289

No abstract available

Keywords: atherosclerosis; biomarkers; precision medicine; residual risk; secondary prevention.

PubMed Disclaimer

Similar articles

Evidence-Based Precision Medicine is Needed to Move Toward General Internal Precision Medicine.
Jaccard E, Cornuz J, Waeber G, Guessous I. Jaccard E, et al. J Gen Intern Med. 2018 Jan;33(1):11-12. doi: 10.1007/s11606-017-4149-0. J Gen Intern Med. 2018. PMID: 28808923 Free PMC article. Review. No abstract available.
Reconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunities.
Beckmann JS, Lew D. Beckmann JS, et al. Genome Med. 2016 Dec 19;8(1):134. doi: 10.1186/s13073-016-0388-7. Genome Med. 2016. PMID: 27993174 Free PMC article. Review.
New technologies personalize diagnostics and therapeutics.
Rosenson RS. Rosenson RS. Curr Atheroscler Rep. 2010 May;12(3):184-6. doi: 10.1007/s11883-010-0103-x. Curr Atheroscler Rep. 2010. PMID: 20425257 Review.
The limitations of evidence-based medicine compel the practice of personalized medicine.
Einav S, O'Connor M. Einav S, et al. Intensive Care Med. 2024 Aug;50(8):1323-1326. doi: 10.1007/s00134-024-07528-y. Epub 2024 Jun 27. Intensive Care Med. 2024. PMID: 38935271 No abstract available.
Precision Medicine Versus Evidence-Based Medicine: Individual Treatment Effect Versus Average Treatment Effect.
Blackstone EH. Blackstone EH. Circulation. 2019 Oct 8;140(15):1236-1238. doi: 10.1161/CIRCULATIONAHA.119.043014. Epub 2019 Oct 7. Circulation. 2019. PMID: 31589490 Review. No abstract available.

See all similar articles

Cited by

Latin American Consensus on management of residual cardiometabolic risk. A consensus paper prepared by the Latin American Academy for the Study of Lipids and Cardiometabolic Risk (ALALIP) endorsed by the Inter-American Society of Cardiology (IASC), the International Atherosclerosis Society (IAS), and the Pan-American College of Endothelium (PACE).
Ponte-Negretti CI, Wyss FS, Piskorz D, Santos RD, Villar R, Lorenzatti A, López-Jaramillo P, Toth PP, Amaro AJJ, Rodrigo AK, Lanas F, Urina-Triana M, Lara J, Valdés TO, Gomez-Mancebo JR, Bryce A, Cobos S L, Puente-Barragan A, Ullauri-Solórzano VE, Medina-Palomino FA, Lozada AF, Duran M, Berrospi P, Miranda D, Badimon JJ, González JJR, Libby P. Ponte-Negretti CI, et al. Arch Cardiol Mex. 2022 Jan 3;92(1):99-112. doi: 10.24875/ACM.21000005. Arch Cardiol Mex. 2022. PMID: 34187049 Free PMC article.
Real-world outcomes of different treatment strategies in patients with diabetes and three-vessel coronary disease: a mean follow-up 6.3 years study from China.
Zhao X, Xu L, Jiang L, Tian J, Zhang Y, Wang D, Sun K, Xu B, Zhao W, Hui R, Gao R, Song L, Yuan J. Zhao X, et al. Cardiovasc Diabetol. 2021 Jan 11;20(1):16. doi: 10.1186/s12933-020-01193-3. Cardiovasc Diabetol. 2021. PMID: 33430864 Free PMC article.
Predictive value of inflammatory prognostic index for contrast-induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention.
Jiang Y, Luo B, Chen Y, Peng Y, Lu W, Chen L, Lin Y. Jiang Y, et al. Sci Rep. 2024 Jul 9;14(1):15861. doi: 10.1038/s41598-024-66880-7. Sci Rep. 2024. PMID: 38982273 Free PMC article.
Reducing residual thrombotic risk in patients with peripheral artery disease: impact of the COMPASS trial.
Hernández JL, Lozano FS, Riambau V, Almendro-Delia M, Cosín-Sales J, Bellmunt-Montoya S, Garcia-Alegria J, Garcia-Moll X, Gomez-Doblas JJ, Gonzalez-Juanatey JR, Suarez Fernández C. Hernández JL, et al. Drugs Context. 2020 Jul 6;9:2020-5-5. doi: 10.7573/dic.2020-5-5. eCollection 2020. Drugs Context. 2020. PMID: 32699549 Free PMC article. Review.
The Prognostic Role of Naples Prognostic Score in Patients with Coronary Artery Disease.
Jiang Y, Chen Y, Lu W, Peng Y, Chen L, Lin Y. Jiang Y, et al. J Inflamm Res. 2025 May 30;18:6999-7012. doi: 10.2147/JIR.S527868. eCollection 2025. J Inflamm Res. 2025. PMID: 40463862 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information